25 May 2013
Keywords: Geron, Human embyonic stem cell-based therapy, GRNOPC1
Article | 13 October 2010
Less than two months after the US government lifted its clinical hold on such research, Geron Corp (Nasdaq: GERN) has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 October 2010
12 October 2010
24 May 2013
© 2013 thepharmaletter.com